Fulgent Genetics (FLGT) Gains from Sales and Divestitures (2017 - 2025)

Fulgent Genetics has disclosed Gains from Sales and Divestitures across 9 years of filings, most recently posting $1.0 million for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $1.0 million, up 4.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 4.48% YoY), and the FY2025 annual result was $1.0 million, up 4.48% from the prior year.
• Gains from Sales and Divestitures came in at $1.0 million for Q4 2025 at Fulgent Genetics, up from $1.0 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2023 to a low of $699000.0 in Q4 2022.
• The 5-year median for Gains from Sales and Divestitures is $1.0 million (2024), against an average of $930800.0.
• Across the five-year window, Gains from Sales and Divestitures declined 16.39% in 2022 and soared 52.5% in 2023, its largest moves.
• Fulgent Genetics' Gains from Sales and Divestitures stood at $836000.0 in 2021, then slipped by 16.39% to $699000.0 in 2022, then surged by 52.5% to $1.1 million in 2023, then decreased by 5.82% to $1.0 million in 2024, then grew by 4.48% to $1.0 million in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.0 million (Q4 2025), $1.0 million (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.